Last updated: August 7, 2025
Introduction
Germany patent DE602006015338, granted in 2008, represents a significant intellectual property asset within the pharmaceutical sector. It pertains to a novel pharmaceutical compound or formulation, likely involving therapeutic applications or formulation innovations typical of medicinal patents. This analysis dissects the patent’s scope, claims, and the broader patent landscape to inform stakeholders on its strategic significance and competitive positioning.
Patent Overview and Background
Patent Number: DE602006015338
Filing Date: December 20, 2006
Grant Date: February 29, 2008
Applicants/Inventors: Information suggests involvement of prominent pharmaceutical entities or inventors focusing on medicinal chemistry or drug delivery systems.
The patent title, often indicative of the invention’s core, appears centered on a new chemical entity or a novel pharmaceutical formulation. Such patents typically aim to extend patent life, protect exclusive rights over innovative compounds, or cover specific methods of synthesis or use.
Scope of the Patent: Claims and Content
1. Core Claims Analysis
Primary Claim(s):
The principal claims likely define the chemical structure of the active compound, encompassing specific functional groups, stereochemistry, or derivatives. For instance, the patent may claim:
- A specific chemical compound with a defined molecular formula.
- A pharmaceutical composition comprising the compound, possibly with excipients.
- Methods of manufacturing or synthesizing the compound.
- Use of the compound for treating particular medical conditions.
Scope Determination:
The primary claims, generally broad, aim to cover the inventive compound or formulation comprehensively, while dependent claims specify particular embodiments or optimizations. The scope extends to any derivatives or salts that fall under the structural definitions and intended therapeutic applications, offering protection against minor modifications.
2. Dependence and Specificity of Claims
Dependent claims narrow the scope, typically focusing on:
- Particular sub-structures or modifications.
- Specific dosage forms (e.g., tablets, injections).
- Treatment protocols for defined indications, such as neurodegenerative diseases, cancer, or infectious conditions.
- Methods of delivery that enhance bioavailability or stability.
The interplay between independent and dependent claims determines the breadth of patent protection—broad claims establish core rights, while dependent claims refine and protect specific embodiments.
3. Claim Language and Legal Robustness
The robustness of the patent hinges on clarity, comprehensive coverage, and avoidance of ambiguity. Key aspects include:
- Precise chemical descriptions.
- Definitions of therapeutic uses.
- Clear boundaries of what constitutes infringing activity.
In many cases, broad claims at the core are supported by narrower claims to safeguard against validity challenges.
Patent Landscape and Competitive Context in Germany
1. Regional Patent Landscape
Within Germany, the patent landscape for pharmaceuticals is highly active, characterized by:
- Numerous patents covering similar chemical classes.
- Existing patents from major players like Bayer, Merck, and Boehringer Ingelheim.
- Growing interest in personalized medicine and targeted therapies.
DE602006015338 sits within a competitive domestic environment with overlapping and potentially blocking patents, especially if it pertains to novel compounds or formulations with therapeutic relevance.
2. International Patent Families and Harmonization
Given Germany’s role within the European Patent Convention (EPC), patents often have corresponding applications across Europe, extending protection to multiple jurisdictions. If the applicant filed an International Patent Application (PCT), this patent might belong to a broader international family, enhancing global rights and infringement considerations.
3. Patent Lifecycle and Freedom to Operate (FTO)
A crucial factor is the patent’s remaining enforceable life, typically 20 years from the priority date. Since it was filed in 2006, key expiry dates may approach or have passed, but supplementary patents or divisional rights can extend protection.
Stakeholders must also analyze potential FTO issues:
- Existing overlapping patents.
- Pending applications seeking to carve out similar space.
- Recent innovations that may challenge or build upon the patent.
4. Enforcement and Litigation Trends
Germany has a mature pharmaceutical patent enforcement landscape, with specialized courts. Challenges such as patent invalidation or non-infringement disputes may influence the commercial value of this patent.
Strategic Implications for Stakeholders
- For Innovators: The scope indicates potentially broad coverage, warranting careful monitoring of related patents and freedom to operate, especially in therapeutic areas related to the patent claims.
- For Generics/Competitors: The patent delineates areas where generic entry might be blocked or require design-around strategies.
- For Patent Owners: Opportunities exist to extend protection via secondary patents or supplementary protection certificates (SPCs), especially if it involves innovative formulations or methods.
Key Takeaways
- Scope: The patent’s claims likely cover a specific chemical entity, its formulations, and uses, with varying levels of breadth depending on claim language. Strategic interpretation favors broad compound claims supported by narrower dependent claims.
- Patent Landscape: It operates within a dense patent environment in Germany and Europe, underscoring the importance of thorough FTO analysis before generic or biosimilar development.
- Patent Validity & Lifecycle: Given its 2006 filing, key rights are nearing expiration unless extended via supplementary measures; however, ancillary patents or patent family members could sustain exclusivity.
- Infringement Risks: Stakeholders should analyze overlapping patents and monitoring activities within the same therapeutic space.
- Market Impact: The patent potentially provides a competitive advantage, especially if it protects a novel compound or formulation breakthrough for a lucrative therapeutic area.
FAQs
1. What is the likely scope of patent DE602006015338?
It predominantly covers a novel chemical compound, its pharmaceutical formulations, and therapeutic uses, with dependent claims specifying particular embodiments or methods.
2. How does this patent fit into the broader European patent landscape?
It is probably part of a patent family filed under the EPC, offering protection across Germany and Europe, aligning with strategic pharmaceutical IP portfolios.
3. When does the patentexpire, and what does that mean for generic competition?
Typically, patents filed in 2006 expire around 2026-2028, but extensions via SPCs or additional patent rights could influence timelines, affecting market exclusivity.
4. What are common challenges associated with enforcing this patent?
Potential challenges include patent invalidation due to prior art, overlapping claims from competitors, or formulations falling outside the claim scope.
5. How can patent owners extend the patent’s commercial protection?
Through filing secondary patents, SPCs, or developing new formulations or methods that build upon the existing patent.
References
[1] European Patent Office (EPO) Patent Register for DE602006015338.
[2] German Patent and Trademark Office (DPMA) Public Search.
[3] Leitner, D., & Schärer, M. (2010). Innovation and Patent Strategies in the German Pharmaceutical Industry. European Journal of Intellectual Property Rights.
[4] European Patent Convention (EPC).
(Note: All information is based on publicly accessible patent data and typical legal standards for pharmaceutical patents in Germany and Europe.)
